Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

Abstract There is an urgent need to develop new life‐prolonging therapy for pancreatic ductal adenocarcinoma (PDAC). It is demonstrated that improved irinotecan delivery by a lipid bilayer coated mesoporous silica nanoparticle, also known as a silicasome, can improve PDAC survival through a chemo‐im...

Full description

Bibliographic Details
Main Authors: Xiangsheng Liu, Jinhong Jiang, Yu‐Pei Liao, Ivanna Tang, Emily Zheng, Waveley Qiu, Matthew Lin, Xiang Wang, Ying Ji, Kuo‐Ching Mei, Qi Liu, Chong Hyun Chang, Zev A. Wainberg, Andre E. Nel, Huan Meng
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Advanced Science
Subjects:
autophagy
chemo‐immunotherapy
irinotecan silicasome
pancreatic cancer
PD‐1/PD‐L1 axis
Online Access:https://doi.org/10.1002/advs.202002147

Internet

https://doi.org/10.1002/advs.202002147

Similar Items